论文部分内容阅读
目的:研究莫西沙星与左氧氟沙星治疗耐多药肺结核的临床疗效及药物不良反应。方法:选择我院自2011年2月-2014年2月收治的120例耐多药肺结核患者,按照随机对照原则分为两组,观察组与对照组各60例,给予观察组莫西沙星和利福布汀进行联合治疗,对照组则给予左氧氟沙星和利福喷丁进行联合治疗,两组其余的抗结核药物均应用氨基水杨酸异烟肼、丙硫异烟胺、吡嗪酰胺、丁胺卡那霉素等,治疗18个月后对两组患者病灶吸收、空洞闭合、痰菌转阴率及复发率等情况进行对比。结果:观察组治愈率,病灶吸收率、空洞闭合率、不良反应发生及痰菌转阴率均显著优于对照组,差异具有统计学意义(P<0.05)。结论:莫西沙星联合利福布汀对耐多药肺结核的治疗效果优于左氧氟沙星联合利福布汀。
Objective: To study the clinical efficacy and adverse drug reactions of moxifloxacin and levofloxacin in the treatment of multi-drug resistant pulmonary tuberculosis. Methods: A total of 120 MDR-TB patients admitted to our hospital from February 2011 to February 2014 were randomly divided into two groups: observation group (60 cases) and control group (60 cases). Moxifloxacin and Rifabutin combination therapy, while the control group was given levofloxacin and rifapentine combination therapy, the remaining two groups of anti-TB drugs are applied aminosalicylate isoniazid, propylthiouracil, pyrazinamide, Ding Amikacin, etc., after 18 months of treatment of two groups of patients with lesions absorbed, empty closed, sputum negative rate and recurrence rates were compared. Results: The cure rate, lesion absorption rate, void closure rate, incidence of adverse reactions and sputum negative conversion rate in the observation group were significantly better than those in the control group, with statistical significance (P <0.05). Conclusion: Moxifloxacin combined with rifabutin is superior to levofloxacin and rifabutin in the treatment of multidrug-resistant pulmonary tuberculosis.